Microflora changes with the use of a vaginal microbicide

Sexually Transmitted Diseases

Volumn 29, Issue 5, 2002, Pages 288-293

  Clarke, Jennifer G ^a   Peipert, Jeffrey F ^a   Hillier, Sharon L ^a   Heber, Walter ^a   Boardman, Lori ^a   Moench, Thomas R ^a   Mayer, Kenneth ^a  

^a Division of Research Women and Infants Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPOL 974P; SPERMICIDAL AGENT;

ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTOBACILLUS; VAGINA FLORA; VIRUS INHIBITION;

EID: 0036254129     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200205000-00007     Document Type: Article

References (35)

1. Global burden of the HIV pandemic
2. AIDS in women in the United States: Recent trends
3. The effectiveness of condoms in reducing heterosexual transmission of HIV
4. Challenges for the development of female controlled vaginal microbicides
5. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro
6. A controlled trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases
7. Efficacy of nonoxynol-9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes
8. Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects
9. Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission
10. Bacterial vaginosis and disturbances of vaginal flora: Association with increased acquisition of HIV
11. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition
12. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection
13. The rate at which human sperm are immobilized and killed by mild acidity
14. Comparative study of inactivation of herpes simplex virus types 1 and 2 by commonly used antiseptic agents
15. Biology of Neisseria gonorrhoeae
16. Response of gonococcal clinical isolates to acidic conditions
17. Effect of pH on the motility and virulence of Treponema pallidum (Nichols) and Treponema paraluis cuniculi in vitro under anaerobic conditions
18. Characteristics of Haemophilus ducreyi in culture
19. Acid sensitivity of cell-free and cell-associated HIV-I: Clinical implications
20. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro
21. Final report on the safety assessment of carbomers-934, -910, -934P, -940, -941, and -962
22. Evaluating microbicides for prevention of chlamydia infection using a mouse model of vaginal transmission
23. Tests of BufferGel in animal models for contraception and prevention of sexually transmitted infections
24. Safety and tolerability of BufferGel, a novel vaginal microbicide studied in U.S. women
25. 2-producing lactobacilli, and bacterial vaginosis in pregnant women
26. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent
27. Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients
28. Effects of chlorhexidine gluconate douche on normal vaginal flora
29. A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: A novel potential intravaginal virucide
30. Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1
31. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infections
32. Phase I trial of the topical microbicide BufferGel: Safety results from four international sites
33. The effects of three nonoxynol-9 preparations on vaginal flora and epithelium
34. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis